Nwam LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 6.4% in the third quarter, HoldingsChannel.com reports. The fund owned 85,618 shares of the biopharmaceutical company’s stock after selling 5,856 shares during the quarter. Nwam LLC’s holdings in Pfizer were worth $3,142,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Hudson Bay Capital Management LP boosted its stake in shares of Pfizer by 2.2% in the second quarter. Hudson Bay Capital Management LP now owns 230,000 shares of the biopharmaceutical company’s stock worth $7,521,000 after acquiring an additional 5,000 shares during the period. Argus Investors Counsel Inc. lifted its position in shares of Pfizer by 5.3% in the second quarter. Argus Investors Counsel Inc. now owns 108,480 shares of the biopharmaceutical company’s stock worth $3,547,000 after buying an additional 5,500 shares in the last quarter. AE Wealth Management LLC lifted its position in shares of Pfizer by 35.0% in the second quarter. AE Wealth Management LLC now owns 376,967 shares of the biopharmaceutical company’s stock worth $12,327,000 after buying an additional 97,799 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Pfizer by 21.2% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 15,704 shares of the biopharmaceutical company’s stock worth $514,000 after buying an additional 2,744 shares in the last quarter. Finally, Bank of Nova Scotia Trust Co. lifted its position in shares of Pfizer by 6.1% in the second quarter. Bank of Nova Scotia Trust Co. now owns 80,342 shares of the biopharmaceutical company’s stock worth $2,627,000 after buying an additional 4,591 shares in the last quarter. 69.08% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently commented on PFE. Berenberg Bank began coverage on Pfizer in a research report on Tuesday, September 29th. They issued a “hold” rating and a $38.00 target price on the stock. UBS Group boosted their target price on Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 29th. Piper Sandler boosted their target price on Pfizer from $18.50 to $24.00 in a research report on Friday, June 26th. Mizuho restated a “buy” rating and set a $43.00 price objective on shares of Pfizer in a research report on Tuesday, September 15th. Finally, Royal Bank of Canada set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $39.64.

In other Pfizer news, Director Ronald E. Blaylock bought 13,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were purchased at an average price of $38.55 per share, with a total value of $501,150.00. Following the completion of the purchase, the director now owns 4,000 shares in the company, valued at approximately $154,200. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.08% of the company’s stock.

Shares of PFE traded up $1.40 during mid-day trading on Friday, reaching $37.95. 40,790,772 shares of the company’s stock traded hands, compared to its average volume of 28,495,957. The stock has a market cap of $210.88 billion, a P/E ratio of 15.06, a P/E/G ratio of 2.91 and a beta of 0.67. The stock’s 50-day moving average is $36.59 and its two-hundred day moving average is $36.32. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $40.97. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.14. The firm had revenue of $11.80 billion for the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The company’s quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.80 earnings per share. Research analysts predict that Pfizer Inc. will post 2.89 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be paid a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. Pfizer’s dividend payout ratio is 51.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: What is Forex?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.